Novartis Ag (NVSEF) — 6-K Filings

6-K Filings (23)

• 6-K Filing — Nov 25, 2025
• Novartis Projects 5-6% Sales CAGR 2025-2030 — Nov 20, 2025 Risk: low
  Novartis AG announced on November 20, 2025, that it projects a 5-6% compound annual growth rate (CAGR) in constant currency (cc) sales from 2025 to 2030. This m
• Novartis Issues Over $5 Billion in Notes — Nov 5, 2025 Risk: low
  Novartis AG, through its subsidiary Novartis Capital Corporation, announced the issuance of several tranches of notes on November 5, 2025. These include $800 mi
• Novartis AG Files Q3 2025 Financial Report on Form 6-K — Oct 28, 2025 Risk: low
  Novartis AG filed a Form 6-K on October 28, 2025, reporting on its financial performance for the period ending September 30, 2025. The filing includes Exhibits
• Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences — Oct 27, 2025 Risk: medium
  Novartis AG announced on October 27, 2025, an agreement to acquire Avidity Biosciences, a company focused on RNA therapeutics. This acquisition aims to bolster
• FDA Approves Novartis' Rhapsido for Chronic Spontaneous Urticaria — Sep 30, 2025 Risk: low
  Novartis AG announced on September 30, 2025, that the FDA has approved Rhapsido® (remibrutinib). This is the only oral, targeted BTKi treatment for chronic spon
• Novartis ianalumab trials meet Sjögren's disease endpoints — Aug 11, 2025 Risk: low
  Novartis AG announced on August 11, 2025, that its Phase III clinical trials, NEPTUNUS-1 and NEPTUNUS-2, for ianalumab in patients with Sjögren's disease, met t
• Novartis AG Files Q2 2025 Financial Report — Jul 17, 2025 Risk: low
  Novartis AG filed a Form 6-K on July 17, 2025, reporting its financial results for the period ending June 30, 2025. The filing includes Exhibit 99.1, the Financ
• Novartis Appoints Mukul Mehta as New CFO, Harry Kirsch Retires — Jul 17, 2025 Risk: low
  Novartis AG announced on July 17, 2025, that Mukul Mehta will become the new Chief Financial Officer (CFO) effective March 16, 2026. Mehta, currently Head of Bu
• Novartis Pluvicto Shows Strong Prostate Cancer Benefit — Jun 2, 2025 Risk: low
  Novartis AG announced on June 2, 2025, that its drug Pluvicto™ demonstrated a statistically significant and clinically meaningful improvement in radioligand pro
• Novartis AG Files Q1 2025 Financial Report — Apr 29, 2025 Risk: low
  Novartis AG filed a Form 6-K on April 29, 2025, reporting its Q1 2025 financial results. The filing includes Exhibit 99.1, a Financial Report for Q1 2025, and E
• Novartis Vanrafia® Gets FDA Accelerated Approval for IgAN — Apr 3, 2025 Risk: low
  Novartis AG announced on April 3, 2025, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan). This drug
• FDA OKs Earlier Pluvicto Use for Prostate Cancer — Mar 28, 2025 Risk: low
  On March 28, 2025, Novartis AG announced that the U.S. Food and Drug Administration (FDA) has approved an earlier use of its radioligand therapy, Pluvicto®, for
• Novartis SMA Drug Hits Phase III Endpoint — Dec 30, 2024 Risk: low
  Novartis AG announced on December 30, 2024, that its Phase III study for intrathecal onasemnogene abeparvovec met its primary endpoint in children and young adu
• Novartis Upgrades Guidance, Highlights Pipeline — Nov 25, 2024 Risk: low
  Novartis AG announced on November 21, 2024, that it is upgrading its mid-term guidance and emphasizing its pipeline to drive long-term growth. The company highl
• Novartis AG Files Q3 2024 Financial Report — Oct 29, 2024 Risk: low
  Novartis AG filed a Form 6-K on October 29, 2024, reporting its Q3 2024 financial results. The filing includes a Financial Report for Q3 2024 and an Interim Fin
• Novartis Scemblix FDA Approved for Newly Diagnosed CML — Oct 29, 2024 Risk: low
  Novartis AG announced on October 29, 2024, that the U.S. Food and Drug Administration (FDA) has approved Scemblix® (asciminib) for the treatment of newly diagno
• Novartis Issues Over $3.7 Billion in New Notes — Sep 18, 2024 Risk: low
  Novartis AG, through its subsidiary Novartis Capital Corporation, announced the issuance of new notes on September 18, 2024. The issuance includes $1,000,000,00
• FDA Approves Novartis Kisqali for Early Breast Cancer — Sep 17, 2024 Risk: low
  On September 17, 2024, Novartis AG announced that the U.S. Food and Drug Administration (FDA) approved Kisqali® (ribociclib) to reduce the risk of recurrence in
• Novartis Fabhalta FDA Accelerated Approval for IgAN — Aug 8, 2024 Risk: low
  Novartis AG announced on August 7, 2024, that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Fabhalta® (iptacopan). This drug is t
• Novartis AG Files Q2 2024 Financial Report — Jul 18, 2024 Risk: low
  Novartis AG filed a Form 6-K on July 18, 2024, reporting its financial information as of June 30, 2024. The filing includes Exhibit 99.1, a Financial Report for
• Novartis AG Files Q1 2024 Financial Reports — Apr 23, 2024 Risk: low
  Novartis AG filed a Form 6-K on April 23, 2024, reporting on its Q1 2024 financial results. The filing includes a Financial Report for Q1 2024 and an Interim Fi
• Novartis Scemblix® Beats Standard TKIs in CML Phase III Trial — Jan 8, 2024
  Novartis AG announced on January 8, 2024, that its drug Scemblix® (asciminib) achieved superior major molecular response (MMR) rates compared to standard-of-car

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX